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Abstract 
Purpose: To compare the effects of two anti-angiogenic drugs, bevacizumab and a 
cytosolic phospholipase A2-α inhibitor (AVX235), on the relationship between vascular 
structure and dynamic contrast enhanced (DCE)-MRI measurements in a patient-derived 
breast cancer xenograft model. 
Methods: Mice bearing MAS98.12 tumors were randomized into three groups: 
bevacizumab-treated (n=9), AVX235-treated (n=9), and control (n=8). DCE-MRI was 
performed pre-and post-treatment. The median initial area under the concentration-time 
curve (IAUC60) and volume transfer constant (Ktrans) were computed for each tumor. The 
tumors were excised for ex vivo micro-CT angiography, from which the vascular surface 
area (VSA) and fractional blood volume (FBV) were computed. Spearman correlation 
coefficients (ρ) were computed to evaluate the associations between the DCE-MRI and 
micro-CT parameters. 
Results: With the groups pooled, IAUC60 and Ktrans correlated significantly with VSA 
(ρ=0.475 and 0.527, P=0.019 and 0.008). There were no significant correlations within 
the control group. There were various significant correlations within the treatment groups 
but the correlations in the bevacizumab group were of opposite sign, e.g., Ktrans vs. FBV: 
AVX235 ρ=0.800 (P=0.014), bevacizumab ρ=-0.786 (P=0.023). 
Conclusion: DCE-MRI measurements can highly depend on vascular structure. The 
relationship between vascular structure and function changed markedly after anti-
angiogenic treatment. 
 




DCE-MRI provides information on vascular function (blood flow, permeability), and DCE-
MRI biomarkers are frequently incorporated into clinical trials of anti-angiogenic therapies 
(1). Currently recommended biomarkers to measure include the initial area under the 
contrast agent concentration-time curve at 60 seconds post-injection (IAUC60) and the 
volume transfer constant (Ktrans) derived from the Tofts model (2-4). Both of these are 
composite parameters that depend on a combination of blood flow and vessel 
permeability-surface area product (PS). The dependence of these DCE-MRI parameters 
on multiple factors can make their physiological interpretations ambiguous. However, they 
have shown promise as biomarkers of cancer treatment response, suggesting that 
physiologically specific biomarkers may not be essential for clinical decision making (5). 
Still, separate measurements of biological factors can be interesting and helpful, e.g., in 
studying drug mechanisms of action or in certain clinical cases (6,7). Generalized 
pharmacokinetic models can provide individual estimates of blood plasma volume fraction 
(vp), extravascular-extracellular space volume fraction (ve), blood flow, and PS (8); but 
these models have not been widely adopted for DCE-MRI analysis. 
Regardless of the method of analysis, DCE-MRI is often discussed in the context of blood 
flow and permeability (i.e., vascular function) while the surface area component of the PS 
product (i.e., vascular structure) is largely ignored. A search for “DCE-MRI” on PubMed 
(August 15, 2016) yielded 1929 results; of those, 246 also include the term “flow”, 342 
include “permeability”, and only 40 include “surface area”. This illustrates that relatively 
few studies have explicitly investigated how vascular morphology influences DCE-MRI 
measurements or how this relationship is affected by treatment (9-11). (Throughout the 
manuscript, vascular morphology/structure refer to the “macroscopic” form of the vascular 
network and not cellular morphology of the endothelium and perivascular components). 
In this study, we addressed these questions by comparing in vivo DCE-MRI parameters 
to ex vivo micro-CT vascular morphometrics and histology in a patient-derived xenograft 
model of breast cancer treated with two different anti-angiogenic agents: 1) bevacizumab 
(Avastin®, Genentech Inc., South San Francisco, CA, USA), a monoclonal antibody 
against vascular endothelial growth factor A, the main driver of tumor angiogenesis (12); 
and 2) AVX235 (Avexxin AS, Trondheim, Norway), a small molecule inhibitor of group 
IVA cytosolic phospholipase A2-α, a pro-inflammatory and pro-angiogenic enzyme that 




MAS98.12 patient-derived basal-like/triple-negative breast cancer xenografts were 
bilaterally and orthotopically transplanted into the thoracic mammary fat pads of 26 female 
Hsd:Athymic Nude-Foxn1nu mice. The establishment and maintenance of the tumor 
model is described in (17). Details of animal housing and handling can be found in (16). 
All procedures and experiments involving animals were approved by the Norwegian 
Animal Research Authority and carried out according to the European Convention for the 
Protection of Vertebrates used for Scientific Purposes. 
The mice were randomly assigned to one of three groups when the long axis of the larger 
tumor reached ~8 mm as measured by calipers. Baseline MRI was performed on all mice 
(day 0). Afterward, one group (n = 9) received bevacizumab (5 mg/kg i.p., 0.5 mg/mL 
saline) on days 0 and 3; another group (n = 9) received daily doses of AVX235 (45 mg/kg 
i.p., 22.5mg/mL dimethyl sulfoxide) from day 0 to day 6; and a control group (n = 8) 
received daily doses (2 mL/kg) of 100% dimethyl sulfoxide from day 0 to day 6. All mice 
were scanned again on day 4, after which the bevacizumab-treated mice were sacrificed; 
AVX235-treated and control mice were scanned again on day 7 before being sacrificed. 
For the control and AVX235 groups, the DCE-MRI data collected on day 4 was not 
included in this study.  
Previous studies have demonstrated that both drugs inhibit long-term growth of this tumor 
model (16,18). The short duration of this study was chosen in order to investigate the 
early vascular effects of the drugs. 
 
MRI 
MRI was performed on a 7T scanner (BioSpec 70/20 Avance III, Bruker Biospin, Ettlingen, 
Germany) using an 86 mm excitation volume coil and a mouse brain quadrature receiver 
surface coil. The mice were anesthetized with isoflurane (2-2.5% in 67% air/33% O2, 0.6 
L/min); isoflurane levels were adjusted as needed to maintain a respiration rate of ~60 
breaths/min. The animals’ body temperatures were monitored with a rectal probe and 
controlled using a small animal monitoring system (Model 1030, SAII, Stony Brook, NY, 
USA).  
A fast low angle shot sequence was used to acquire 3D images for tumor volume 
measurements: echo time (TE) = 3 ms, repetition time (TR) = 13 ms, flip angle = 30°, 8 
averages, matrix = 256×96×48 zero-padded to 256×128×64, field of view = 20×20×10 
mm3. High-resolution T2-weighted 2D RARE images were acquired to delineate tumor 
regions of interest (ROI): TE = 68 ms, TR = 1500 ms, RARE factor = 16, 4 averages, 
matrix = 256×192 zero-padded to 256×256. A 2D rapid acquisition with relaxation 
enhancement (RARE) sequence with variable TRs was used to compute baseline T1 
maps: effective TE = 13 ms; TR = 225, 500, 1500, 3000, 6000, 12000 ms; RARE factor 
= 2, matrix = 64×48 zero-padded to 64×64. This was followed by the acquisition of a 
dynamic series of 200 T1-weighted images using a 2D RARE sequence: effective TE = 
7.5 ms, TR = 300 ms, RARE factor = 4, matrix = 64×64, temporal resolution = 4.8 s. An 
intravenous bolus injection of 0.3 mmol/kg of gadodiamide (Omniscan, GE Healthcare, 
Oslo, Norway) was administered via the tail vein after the tenth baseline image. All 2D 
scans were acquired with the same geometry: field of view = 20×20 mm2, slice thickness 
= 0.6 mm, interslice gap = 0.3 mm, 4 coronal slices. 
Tumor ROIs, which excluded skin and subcutaneous fat around the tumors, were 
manually drawn on the 3D images for tumor volume measurements, and on the high-
resolution 2D images and down-sampled to the resolution of the other images for DCE-
MRI analysis. The enhancing fraction (EF, fraction of tumor voxels with signal 
enhancement > 50% one minute after contrast agent administration) (19,20) and maps of 
IAUC60 and the extended Tofts model parameters – Ktrans, ve, and vp – were computed 
from the DCE-MRI data. A previously measured population-based bi-exponential arterial 
input function (AIF) was used for pharmacokinetic analysis (21). Tumor-wise parameter 
medians were computed from the maps. Non-enhancing voxels and voxels with poor fits 
(R2 < 0.5) were excluded from these computations and all subsequent analyses.  
 
Micro-CT 
Immediately after the final MRI session, mice were sacrificed by perfusion fixation and 
perfused with Microfil® (Flow Tech, Inc., Carver, MA, USA), a radiopaque vascular 
casting agent. Then, tumors were excised and scanned on a SkyScan 1176 micro-CT 
system (Bruker microCT, Kontich, BE) at 9-μm isotropic resolution. Tumor blood vessels 
were segmented from the micro-CT images using a Hessian-based filtering method 
(22,23). Tumor masks, which excluded any skin and subcutaneous fat remaining after 
excision, were manually drawn on the raw micro-CT images. From the segmented 
vessels and tumor masks, fractional blood volume (FBV), vessel surface area normalized 
to tumor volume (VSA), and median and 90th percentile distances to the nearest vessel 
(DNV and DNV90) were computed for each tumor. DNV is inversely related to overall 
vessel density, while DNV90 is sensitive to the presence of large avascular regions. 
These large avascular regions in the micro-CT images that corresponded to non-
enhancing areas in the DCE-MRI image and necrotic areas in the histology sections were 
extracted from the tumor masks by thresholding the DNV maps. Thresholds were 
manually determined upon visual comparison of the three imaging modalities. These 
regions were excluded from the tumor volume measurements used to compute FBV and 
VSA. Details of the perfusion and micro-CT image acquisition, reconstruction, and 
processing can be found in (16). 
 
Histology 
After micro-CT imaging, the tumors were cut in half approximately along the MRI slice 
plane and embedded in paraffin. Four-μm-thick sections were cut from the center of each 
tumor and stained with Hematoxylin Erythrosine Saffron (HES) for identifying viable tumor 
tissue, or double-stained with lectin (Griffonia simplicifolia lectin I, Vector Laboratories, 
Burlingame, CA, USA) as an endothelial marker for quantifying vascularization and anti-
Ki67 antibody (monoclonal rabbit anti-human Ki67 with cross-reactivity to mouse; Abcam, 
Cambridge, UK) as a proliferation marker. Non-overlapping 10× fields were acquired from 
each lectin-stained tumor section using an Olympus BX41 microscope (Olympus Norge 
AS, Oslo, Norway). Six to 10 fields were acquired for each section to obtain good 
coverage of the viable tumor regions. RGB images were converted to HSV images, and 
lectin-stained endothelium was segmented by simple thresholding of the hue, saturation, 
and value channels. The same manually defined thresholds for each channel were used 
for all images. From the binarized images, the vascular area fraction was computed for 
each tumor.  
 
Statistical analysis  
All statistical analyses were performed in MATLAB (R2015a, MathWorks, Natick, MA, 
USA). Kruskal-Wallis one-way ANOVA was performed to test for a significant difference 
in normalized tumor volume between the three experimental groups on day 4. A two-
tailed Wilcoxon rank-sum test was performed to test for a significant difference in 
normalized tumor volume between control and AVX235-treated tumors on day 7. One-
way MANOVA, Kruskal-Wallis one-way ANOVA, and post-hoc Tukey’s honest significant 
difference (HSD) tests were used for inter-group comparisons of micro-CT parameters 
and changes in DCE-MRI parameters. In addition to testing for differences in the 
multivariate means of multiple groups, the manova1 MATLAB function computes 
canonical variables – orthogonal linear combinations of the original predictor variables 
that maximize the separation between groups. Scatter plots of the first and second 
canonical variables were generated to visualize the separation between groups. 
Spearman correlation coefficients (ρ) were computed to measure the correlation between 
the “functional” DCE-MRI parameters (EF, IAUC60, Ktrans), micro-CT parameters, and 
histological vascular area fraction. For all tests, α = 0.05.  
 
Results 
Pre-treatment DCE-MRI data was not acquired for one bevacizumab-treated mouse due 
to unsuccessful tail vein cannulation. From the micro-CT dataset, one control and one 
bevacizumab-treated tumor were excluded due to incomplete Microfil® perfusion. 
 
Neither therapy resulted in early tumor growth inhibition 
On day 0, the tumor volumes were 176 [135, 198.5] mm3 (median [25th quantile, 75th 
quantile]) for the control group, 192 [111.75, 199.25] mm3 for the AVX235-treated group, 
and 207 [196.5, 280] mm3 for the bevacizumab-treated group. Kruskal-Wallis one-way 
ANOVA and subsequent post-hoc Tukey’s HSD tests showed that the median day 0 
tumor volume was significantly larger in the bevacizumab group than in the AVX235 group 
(P = 0.042). Therefore, tumor volumes were normalized to day 0 values to evaluate the 
therapeutic effects on tumor growth (Figure 1). There were no significant differences in 
median normalized tumor volumes between the three groups on day 4 (P = 0.135, one-
way ANOVA), or between the control and AVX235 groups on day 7 (P = 0.200, two-tailed 
Wilcoxon rank-sum test). 
 
DCE-MRI did not detect differential treatment responses 
One-way MANOVA determined that there were no significant differences between the 
three groups based on the pre- to post-treatment changes in the DCE-MRI parameters 
(P = 0.330). This is visualized by the scatter plot of the first and second canonical 
variables (c1 vs. c2), which shows a high degree of overlap between the groups (Figure 
2 a). There is some partial separation between the control and bevacizumab-treated 
groups, with the AVX235-treated group in between. When looking at the DCE-MRI 
parameters individually (Figure 2 b-f), it becomes apparent that bevacizumab had 
therapeutic effects, e.g., there was a clear decrease in IAUC60 (Figure 2 c). However, 
when accounting for multiple groups and parameters, these effects were not statistically 
significant. 
 
Micro-CT revealed treatment-related differences in vascular morphology 
Micro-CT revealed significant differences in vascular morphology between the 
experimental groups (P < 0.001, one-way MANOVA). There is a clear separation between 
the bevacizumab-treated group and the other two groups along c1, and good separation 
between the AVX235-treated and control groups along c2 (Figure 3 a). 
VSA, and FBV were largest in the control group and smallest in the bevacizumab group 
(Figure 3 b-c), and the opposite trend was observed for DNV (Figure 3 d). These 
parameters were significantly different in the bevacizumab group compared to controls 
(P < 0.01, post-hoc Tukey’s HSD test). There was a significant difference in VSA between 
the AVX235 and bevacizumab groups (P < 0.05). The difference in FBV between the two 
treatment groups was close to statistical significance (P = 0.054). AVX235-treated tumors 
had the largest DNV90 (Figure 3 e), which was significantly different from the DNV90 in 
control tumors (P < 0.01). 
 
DCE-MRI functional parameters correlate with micro-CT vascular morphometrics 
Pooled (all tumors from all groups) and group-wise Spearman ρ values between DCE-
MRI and micro-CT parameters are presented in Table 1. 
With the groups pooled, there was a moderate but significant positive correlation between 
IAUC60 and VSA (P = 0.019); Ktrans also positively correlated with VSA (P = 0.008). There 
was a negative correlation between EF and DNV90 (P = 0.048).  
The correlation coefficients for individual groups revealed interesting effects of treatment 
on the relationship between DCE-MRI and micro-CT measurements. First, there were no 
significant correlations in the control group. Second, the correlations in the bevacizumab 
group were of the opposite sign as those in the AVX235 group.  
Figures 4 and 5 present these trends. With all three groups pooled, IAUC60 and Ktrans 
generally increased with VSA and FBV (Figure 4). This was also the case for the AVX235 
group on its own. The DCE-MRI and micro-CT parameter values were lower in the 
bevacizumab group than in the other groups, contributing to the pooled positive 
correlations. However, there was a negative correlation between the DCE-MRI and micro-
CT parameters within the bevacizumab group. 
Despite this unexpected inverse relationship in the bevacizumab group, we qualitatively 
observed a direct spatial relationship between DCE-MRI and micro-CT within individual 
tumors. Figure 5 c illustrates this – the top tumor is less vascularized than the bottom 
based on the micro-CT data (center column), but has greater IAUC60 in the viable tumor 
area (left); but within each tumor, relatively highly vascularized areas correspond to high 
perfusion (central region of the top tumor) and vice versa (lower right region of the bottom 
tumor).  
 
Tumor perfusion inversely correlates with histological vascularization 
Overall, there was a moderate but significant (P = 0.018) negative correlation between 
IAUC60 and histological vascular area fraction (Table 2, Figure 6 a). The intra-group 
correlation between IAUC60 and vascular area fraction was significant for the control 
group; the intra-group correlation between Ktrans and vascular area fraction was significant 
for the control and bevacizumab groups (Table 2, Figure 6 a-b). 
There were no significant correlations between histological vascular area fraction and the 
micro-CT parameters (Table 2, Figure 6 c-d). The correlation with FBV in the 
bevacizumab group was good but fell just short of statistical significance (P = 0.058). Of 
note, the correlations between micro-CT and histologically measured vascularization 




While tumor growth inhibition did not reach statistical significance within the time frame 
of this experiment, previous studies have demonstrated that both AVX235 and 
bevacizumab inhibit vascular proliferation and long-term tumor growth in the MAS98.12 
model used here (16,18). The DCE-MRI data from this study indicate that the two drugs 
did not have significantly different effects, but the micro-CT data did reveal significant 
differences between the experimental groups. The differences between groups are further 
emphasized by the correlations between the DCE-MRI and micro-CT parameters. Before 
comparing the group-wise correlations, it is worth discussing the pooled correlations and 
the general dependence of DCE-MRI functional parameters on vascular structure. 
 
Pooled correlations show that vascular structure influences DCE-MRI parameters 
The significant positive correlations between IAUC60 and Ktrans and VSA demonstrate that 
DCE-MRI parameters are not only influenced by vascular function, but can also be highly 
dependent on vascular surface area (4). The commonly used extended Tofts model is 
most appropriate and accurate under high flow conditions in which contrast agent 
extravasation is PS-limited (24). Pharmacokinetic analysis can be restricted to fast-
enhancing voxels to ensure that the data satisfies this condition, as was done here. In 
addition, most tumor blood vessels are characteristically leaky and thus highly permeable 
to the low molecular weight gadolinium-based contrast agents used in the clinic. Thus, 
vascular surface area can be the determining factor in contrast agent kinetics in some 
cases.  
It may seem contradictory that IAUC60 correlated positively with VSA but negatively with 
histological vascular area fraction. However, the three imaging modalities report different 
things about the vasculature. This makes it difficult to use one technique to validate 
another, but combining these complementary image data can provide deeper, more 
nuanced insights into tumor vascular biology. To make sound interpretations, one must 
be mindful of exactly what these methods measure and how they differ. DCE-MRI 
characterizes tumor perfusion via functional vessels, micro-CT visualizes the structure of 
these functional vessels, and histological staining marks endothelial cells regardless of 
vessel functionality.  
The lack of correlation between micro-CT and histology can be explained by the 
dysfunctional nature of tumor vasculature, combined with the different vessel populations 
that are detected by each imaging modality. The negative correlation between DCE-MRI 
and histology suggests that increased vascularization from dysregulated tumor 
angiogenesis does not always translate to increased perfusion and may actually be 
counterproductive. Figure 5 b (top row) and Figure 5 c (bottom row) show examples of 
tumor regions that were not perfused based on DCE-MRI and micro-CT but were still 
viable and vascularized based on histology.  
Similarly, a previous study found a negative correlation between Ktrans and histological 
microvessel density in colorectal cancer xenografts (25). But other studies have reported 
moderate to strong positive correlations between DCE-MRI and histological parameters 
(9,10,26), while others showed weak or no correlations (27-29). These discrepancies 
could be due to the wide range of data acquisition and analysis methods that were 
employed; or to the different patient populations, preclinical cancer models, or treatment 
regimens investigated. Considering the high degree of heterogeneity between different 
types of cancer and even within the same cancer type, there is likely concomitant 
heterogeneity in the relationship between tumor vascularization and perfusion.  
 
Group-wise correlations illustrate the complexity and mutability of the interpretation of 
DCE-MRI parameters 
The group-wise correlations revealed interesting and unexpected differences between 
the three experimental groups. The lack of significant correlations between DCE-MRI and 
micro-CT parameters in the control group suggests large inter-tumor heterogeneity in 
vascular phenotype or a decoupling of structure and function in the tumor vasculature. 
This may be a consequence of the characteristically chaotic and hyperpermeable vessels 
that are produced by pathological tumor angiogenesis. In contrast, the direct relationships 
between DCE-MRI and micro-CT in the AVX235-treated tumors suggest that cPLA2 
inhibition resulted in vascular normalization and subsequent recoupling of vascular 
structure and function. 
Analogously, a recent study showed that Ktrans did not correlate with an independent 
measure of PS product (made by quantifying the leakage of a radioactive tracer) in the 
control group of a rat model of lung cancer brain metastasis. But there was a positive 
correlation after bevacizumab treatment, which the authors attributed to therapy-induced 
vascular normalization (30). 
The inverse associations in the bevacizumab-treated group in our study are harder to 
interpret but may indicate improved blood flow as a result of treatment-induced vascular 
pruning and remodeling. This hypothesis is supported by the increase in EF and 
borderline significant positive correlation between FBV and histological vascular area 
fraction in the bevacizumab group, i.e., after bevacizumab treatment, the amount of 
functional vasculature is more closely associated with the total amount of vasculature, as 
is expected in healthy tissue. The negative correlations between DCE-MRI and micro-CT, 
then, reflect the negative correlation between DCE-MRI and histology. 
This suggests that in the bevacizumab group, contrast-agent delivery to the tumor was 
not directly determined by vascular surface area but instead by blood flow. Given that 
dysregulated angiogenesis and subsequent hypervascularization can lead to vascular 
insufficiency in tumors, it is reasonable that fewer, well-functioning vessels can deliver 
greater blood flow (31,32). One possible mechanistic explanation for this is that 
decreased vascular permeability resulted in decreased tumor interstitial fluid pressure (a 
previously reported effect of bevacizumab treatment) and thus improved tumor perfusion 
and delivery of contrast agent to the tumor tissue (33-35). 
This could also explain the increase in EF seen after bevacizumab treatment. While EF 
often decreases after anti-angiogenic and anti-vascular therapies (7,19,36), other studies 
have reported treatment-induced increases in EF, including a previous study investigating 
the effects of bevacizumab on the tumor model used here (20,37,38). 
The disparate correlations between the treatment groups could be the consequence of 
two distinct mechanisms of action leading to differential modifications of the tumor 
vasculature. Alternatively, the difference could represent two distinct time points in a 
common pharmacological progression. Despite the large amount of research on tumor 
angiogenesis and anti-angiogenic therapy, the mechanisms of action of these drugs are 
still not fully understood (39). The results presented here reflect this complexity of tumor 
biology and pharmacodynamics. 
 
Study limitations 
Limitations of this study include the use of a single population-based AIF, which could 
have changed significantly during treatment, and manual injection of contrast agents. The 
use of a power injector for DCE-MRI would have resulted in more uniform AIFs across 
animals and time points, and a perfusion pump would have ensured consistent Microfil® 
perfusion at physiological pressures and thus minimized vessel distortion. Another 
limitation was the nine-micron spatial resolution of the micro-CT scanner, which is not 
enough to detect the smallest capillary-sized vessels. This may have biased the data if 
the proportion of these microvessels varied between experimental groups. As mentioned 
above, postmortem staining of blood vessels in histological sections does not discriminate 
between perfused and non-perfused vessels. For the purposes of validating DCE-MRI 
and other in vivo perfusion imaging techniques, methods such as labeling functional 
vessels via intravital lectin perfusion would be more suitable (40). Given some of the 
unexpected correlations found in this study, the generalizability and reproducibility of 
these vascular structure-function associations should be tested using different tumor 
models, therapies, and contrast agents. 
  
Conclusions 
DCE-MRI parameters such as IAUC60 and Ktrans, largely regarded as measures of vessel 
permeability or blood flow (i.e., vascular function), can be greatly influenced by vascular 
surface area. The relative weights of these three factors can be significantly altered by 
anti-angiogenic therapy, making the interpretation of DCE-MRI measurements difficult. 
This highlights one of the challenges of adopting DCE-MRI parameters as clinical 
biomarkers and emphasizes the need for a better understanding of tumor angiogenesis 
and of the mechanisms of action of anti-angiogenic agents. 
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Figure 1: Tumor growth curves. The tumor volumes were determined from 3D MR images 
and normalized to pre-treatment (day 0) values. The data points and error bars represent 




Figure 2: a) Tumor-wise scatter plot of the first vs. second canonical variables (c1 vs. c2) 
determined by one-way MANOVA of all DCE-MRI parameters (EF, IAUC60, Ktrans, ve, and 
vp). b-f) Box plots of the changes in DCE-MRI parameters from pre- to post-treatment. 
Ctrl: control, AVX: AVX235-treated, Bev: bevacizumab-treated. 
 
 
Figure 3: a) Tumor-wise scatter plot of the first vs. second canonical variables (c1 vs. c2) 
determined by one-way MANOVA of all micro-CT parameters (VSA, FBV, DNV and 
DNV90). b-e) Box plots of the micro-CT parameters. Ctrl: control, AVX: AVX235-treated, 
Bev: bevacizumab-treated. P-values are from post-hoc Tukey’s HSD tests performed 
after Kruskal-Wallis one-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001. 
 
 
Figure 4: Tumor-wise scatter plots of select DCE-MRI vs. micro-CT parameters, and the 
corresponding Deming regression lines for each group. Filled-in data points and solid 
regression lines indicate statistically significant intra-group Spearman correlations (P < 
0.05). Ctrl: control, AVX: AVX235-treated, Bev: bevacizumab-treated. 
 
 
Figure 5: Two example tumors from the a) control, b) AVX235, and c) bevacizumab 
groups. For each group, the top tumor has a smaller FBV than the bottom tumor. Left 
column: a slice of the IAUC60 map (0.6 mm slice thickness). Center column: 540-μm-thick 
(60 slices) maximum intensity projection (MIP) of the segmented micro-CT vasculature 
from the same region. Non-enhancing or non-perfused tumor regions in the DCE-MRI 
and micro-CT images that were excluded from the data analysis are outlined in cyan. 
Right column: corresponding HES-stained histology section. Insets: fields from adjacent 
sections double-stained with lectin (blue) and anti-Ki67 antibody (brown), scale bars = 
200 μm. Top row scale bars = 1 mm. 
  
 
Figure 6: Tumor-wise scatter plots of select DCE-MRI and micro-CT parameters vs. 
histological vascular area fraction, and the corresponding Deming regression lines for 
each group. Filled-in data points and solid regression lines indicate statistically significant 









Table 1. Spearman correlation coefficients (ρ) between DCE-MRI 
and micro-CT parameters 
  VSA FBV DNV DNV90 
EF 
Pooleda -0.125 -0.202 -0.094 -0.407 
Ctrlb 0.714 0.607 -0.393 -0.464 
AVXc 0.383 0.183 -0.55 -0.767 
Bevd -0.738 -0.786 0.619 0.548 
IAUC60 
Pooleda 0.475 0.354 -0.337 -0.236 
Ctrlb 0.179 0.036 0.000 -0.321 
AVXc 0.617 0.800 -0.733 -0.700 
Bevd -0.786 -0.619 0.690 0.714 
Ktrans 
Pooleda 0.527 0.356 -0.319 -0.129 
Ctrlb 0.107 -0.321 0.214 -0.107 
AVXc 0.717 0.800 -0.767 -0.833 
Bevd -0.595 -0.786 0.429 0.381 
Ctrl: control, AVX: AVX235-treated, Bev: bevacizumab-treated 
an = 24, bn = 7, cn = 9, dn = 8 
Bold: ρ is significantly different than zero, P < 0.05, t-test 
 
Table 2. Spearman correlation coefficients (ρ) between histological 
vascular area fraction and DCE-MRI and micro-CT parameters 
 Pooled Ctrl AVXe Bevc 
IAUC60 -0.484a -0.857c -0.217 -0.548 
Ktrans -0.350a -0.786c -0.217 -0.810 
VSA -0.078b -0.464d -0.333 0.476 
FBV 0.104b -0.143d -0.133 0.714 
Ctrl: control, AVX: AVX235-treated, Bev: bevacizumab-treated 
an = 25, bn = 24, cn = 8, dn = 7, en = 9 
Bold: ρ is significantly different than zero, P < 0.05, t-test 
 
